Search results
Showing 271 to 285 of 726 results for innovative
Evidence-based recommendations on tebentafusp (Kimmtrak) for treating uveal melanoma in adults.
Show all sections
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg.
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .
Biographies and registered interests for members of the Technology Appraisal Committee C
Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.
PulmoVista 500 for monitoring ventilation in critical care (MIB203)
NICE has developed a medtech innovation briefing (MIB) on PulmoVista 500 for monitoring ventilation in critical care .
PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)
NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .
NICE has developed a medtech innovation briefing (MIB) on moorLDLS-BI for burn depth assessment .
Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.
View recommendations for TA322Show all sections
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.
Evidence-based recommendations on pixantrone (Pixuvri) for treating relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in adults.
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.